

Prostate Secretory Protein of 94 amino acids (PSP94) ELISA

[Click Here for Detailed EoI Document](#)

About the Technology: The technology is based on a sandwich ELISA principle for the detection of PSP94. In this assay, a polyclonal rabbit anti-human PSP94 antibody is used as the capture antibody, while purified PSP94 obtained from human seminal plasma serves as the standard. Detection is carried out using a polyclonal rat anti-human PSP94 antibody, followed by a goat anti-rat HRP-conjugated secondary antibody for signal generation.

Technology ID: PM-TT-IM-2026-Mar-40

Lead Inventor: Dr. Dhanashree Jagtap

Institute: ICMR – National Institute For Research in Reproductive and Child Health


Technology Domain: In-vitro diagnostics

Disease Area (Broad): Prostate disorders – Prostate cancer (PCa)

Need and utility of the Technology from Public health perspective: Serum PSA has low specificity for prostate cancer, often leading to unnecessary biopsies, especially in the PSA gray zone. The PSP94 ELISA, used as a PSP94/PSA ratio, improves diagnostic specificity and supports cost-effective clinical decision-making.

Technology Readiness level (TRL):

TRL-4: Validated at in house laboratory



Validation Status and Study Outcome:

- Inhouse Validation –Complete
- Efficacy Outcome:
Sensitivity: ~0.23–0.26 ng/mL
Accuracy: ~98–100%

Market Potential: The PSP94 ELISA kit has strong commercialization potential for adoption in government hospitals, private diagnostic laboratories, and cancer centres.

Unmet need: Prostate disorders are highly prevalent among aging male populations, creating sustained demand for accurate and affordable diagnostic tools.

Publication: NA

IP Filing: NA